Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
JAMA Health Forum. 2022 Aug 5;3(8):e222461. doi: 10.1001/jamahealthforum.2022.2461. eCollection 2022 Aug.
High-dose and long-duration opioid prescriptions remain relatively common among children and adolescents, but there is insufficient research on the association of state laws limiting the dose and/or duration of opioid prescriptions (referred to as opioid prescribing cap laws) with opioid prescribing for this group.
To examine the association between state opioid prescribing cap laws and the receipt of opioid prescriptions among children and adolescents.
This repeated cross-sectional study used a difference-in-differences approach accounting for staggered policy adoption to assess the association of state opioid prescribing cap laws in the US from January 1, 2013, to December 31, 2019, with receipt of opioid prescriptions among children and adolescents. Analyses were conducted between March 22 and December 15, 2021. Data were obtained from the OptumLabs Data Warehouse, a national commercial insurance claims database. The analysis included 482 118 commercially insured children and adolescents aged 0 to 17 years with full calendar-year continuous insurance enrollment between 2013 and 2019. Individuals were included for every year in which they were continuously enrolled; they did not need to be enrolled for the entire 7-year study period. Those with any cancer diagnosis were excluded from analysis.
Implementation of a state opioid prescribing cap law between January 1, 2017, and July 1, 2019. This date range allowed analysis of the same number years for both pre-cap and post-cap data.
Outcomes of interest included receipt of any opioid prescription and, among those with at least 1 opioid prescription, the mean number of opioid prescriptions, mean morphine milligram equivalents (MMEs) per day, and mean days' supply.
Among 482 118 children and adolescents (754 368 person-years of data aggregated to the state-year level), 245 178 (50.9%) were male, with a mean (SD) age of 9.8 (4.8) years at the first year included in the sample (data on race and ethnicity were not collected as part of this data set, which was obtained from insurance billing claims). Overall, 10 659 children and adolescents (2.2%) received at least 1 opioid prescription during the study period. Among those with at least 1 prescription, the mean (SD) number of filled opioid prescriptions was 1.2 (0.8) per person per year. No statistically significant association was found between state opioid prescribing cap laws and any outcome. After opioid prescribing cap laws were implemented, a -0.001 (95% CI, -0.005 to 0.002) percentage point decrease in the proportion of youths receiving any opioid prescription was observed. In addition, percentage point decreases of -0.01 (95% CI, -0.10 to 0.09) in high-dose opioid prescriptions (>50 MMEs per day) and -0.02 (95% CI, -0.12 to 0.08) in long-duration opioid prescriptions (>7 days' supply) were found after cap laws were implemented.
In this cross-sectional study, no association was observed between state opioid prescribing cap laws and the receipt of opioid prescriptions among children and adolescents. Alternative strategies, such as opioid prescribing guidelines tailored to youths, are needed.
高剂量和长时间的阿片类药物处方在儿童和青少年中仍然相对常见,但关于限制阿片类药物处方剂量和/或持续时间的州法律(称为阿片类药物处方上限法)与该人群阿片类药物处方之间的关联的研究还不够充分。
研究州阿片类药物处方上限法与儿童和青少年接受阿片类药物处方之间的关联。
设计、设置和参与者:这项重复的横断面研究采用了差异-差异方法,考虑了政策的交错采用,以评估美国从 2013 年 1 月 1 日至 2019 年 12 月 31 日的州阿片类药物处方上限法与儿童和青少年接受阿片类药物处方之间的关联。分析于 2021 年 3 月 22 日至 12 月 15 日之间进行。数据来自 OptumLabs 数据仓库,这是一个全国性的商业保险索赔数据库。分析包括 482118 名年龄在 0 至 17 岁之间的商业保险儿童和青少年,他们在 2013 年至 2019 年期间有完整的日历年连续保险登记。分析包括他们每年连续登记的情况;他们不需要在整个 7 年的研究期间都进行登记。排除任何癌症诊断的个体进行分析。
2017 年 1 月 1 日至 2019 年 7 月 1 日期间实施州阿片类药物处方上限法。这一日期范围允许对前后上限数据进行相同数量的年份分析。
感兴趣的结果包括任何阿片类药物处方的接受情况,以及在至少有 1 份阿片类药物处方的情况下,平均阿片类药物处方数量、平均每天的吗啡毫克当量(MME)和平均供应天数。
在 482118 名儿童和青少年(754368 人年数据汇总到州年水平)中,245178 名(50.9%)为男性,在纳入样本的第一年(该数据集未收集种族和民族的数据,是从保险计费索赔中获得的),平均年龄(SD)为 9.8(4.8)岁。总体而言,10659 名儿童和青少年(2.2%)在研究期间至少接受了 1 次阿片类药物处方。在至少有 1 次处方的人群中,每年每人平均(SD)开具 1.2(0.8)份阿片类药物处方。研究发现,州阿片类药物处方上限法与任何结果之间均无统计学显著关联。在实施阿片类药物处方上限法后,观察到接受任何阿片类药物处方的青少年比例下降了 0.001(95%CI,-0.005 至 0.002)个百分点。此外,在实施上限法后,高剂量阿片类药物处方(>50 MME/天)和长时间阿片类药物处方(>7 天供应量)的比例分别下降了 0.01(95%CI,-0.10 至 0.09)和 0.02(95%CI,-0.12 至 0.08)。
在这项横断面研究中,未观察到州阿片类药物处方上限法与儿童和青少年接受阿片类药物处方之间存在关联。需要采取替代策略,例如针对青少年的阿片类药物处方指南。